Fig. 1.The workflow of this study. Briefly, a total of 273 eligible BC
patients were enrolled in the radiomic analysis. Based on the molecular subtypes
classification by IHC or FISH assay, BC patients were divided into different
groups for comparison, including Luminal vs. Non-luminal, HER2+ vs. HER2– and TN
vs. Non-TN. Radiomic analysis in the study mainly consist of lesion segmentation,
radiomic features extraction and selection, multivariate radiomic signature model
construction, and evaluation of the predictive performance of the developed
radiomic signature model in molecular subtypes classification of BC by ROC
analysis. Apart from radiomic analysis, a total of 5 conventional PET parameters
(SUVmax, SUVmean, SUVpeak, MTV and TLG) were also calculated to compare their
abilities to discriminate between different molecular subytypes of BC with that
of established radiomic signature model.
BC, breast cancer; CT, computed tomography; FISH, fluorescence in situ
hybridization; HER2, human epidermal growth factor receptor 2; IHC,
immunohistochemistry; MTV, metabolic tumor volume; PET, positron emission
tomography; ROC, receiver operating curve; SUV, standardized uptake value; TLG,
total lesion glycolysis; TN, non-triple.